20 Recruiting Studies Using Gilteritinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Gilteritinib
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Acute Myeloid Leukemia, in Relapse
View Study & Checklist ➔A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
📍 City of Hope Nat'l Medical Center — Duarte, California
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
Myeloid Leukemia
View Study & Checklist ➔Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
📍 Vancouver General Hospital — Vancouver, British Columbia
Acute Myeloid Leukemia
View Study & Checklist ➔Gilteritinib for the Treatment of ALK NSCLC
📍 Cedars-Sinai Medical Center — Los Angeles, California
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
📍 Mayo Clinic Arizona — Phoenix, Arizona
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
View Study & Checklist ➔Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
📍 MD Anderson Cancer Center — Houston, Texas
Targeted Therapy
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
📍 Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center — Fullerton, California
Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
📍 Moffitt Cancer Center — Tampa, Florida
Acute Myeloid Leukemia With FLT3/ITD Mutation
View Study & Checklist ➔A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Biphenotypic Leukemia
View Study & Checklist ➔A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
📍 Hoag Family Cancer Center — Newport Beach, California
Leukemia, Myeloid, Acute
View Study & Checklist ➔Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
AML
View Study & Checklist ➔A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
📍 Children's Hospital of Alabama — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
📍 UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Acute Myeloid Leukemia With FLT3/ITD Mutation
View Study & Checklist ➔